Histological changes were observed in skin treated with a product developed to target changes in the extracellular matrix associated with aging, in a study of six patients in their 60s.
The results were presented in a poster at the Summit in Aesthetic Medicine held by Global Academy for Medical Education.
The product, which contains tripeptide and hexapeptide ingredients, was applied to the forearms and preauricular regions of the participants, which were biopsied 3-8 weeks later. Compared with biopsies at baseline, the investigators found evidence of changes in the extracellular matrix, with “changes in collagen and elastin ... with mature old collagen replaced by freshened new collagen,” as well as “upregulated and redistributed elastin,” and “thickened epidermis with healthy cuboidal basal cells” that replaced flattened cells in the dermoepidermal junction, according to the poster
The study was limited by the small sample of patients, the authors noted. This study was sponsored by Alastin Skincare, the product’s manufacturer. The lead author, Antoanella Calame, MD, chief of dermatology at Scripps Memorial Hospital, La Jolla, California, disclosed consulting fees from Alastin. The other author, Alan Widgerow, MD, professor of plastic surgery at University of California, Irvine, is the chief medical officer of Alastin.
Global Academy and this news organization are owned the same company.
ezimmerman@frontlinemedcom.com
On Twitter @eaztweets